Drug Metabolism Explained: Phase I and Phase II Reactions

Added:

The Non-Sequential Paradigm and Phase III Integration

While textbooks traditionally present drug metabolism as a linear, sequential pathway—where Phase I functionalization must precede Phase II conjugation in the liver—modern pharmacokinetics challenges this oversimplified model. In reality, many drugs undergo Phase II conjugation directly without prior Phase I modification, or even undergo Phase II reactions before Phase I. Furthermore, this classic framework often neglects 'Phase III' transporters (such as P-glycoprotein and multidrug resistance-associated proteins), which actively pump drugs and their metabolites across cell membranes. These transporters operate in tandem with metabolic enzymes rather than as a final step, heavily dictating drug bioavailability. Additionally, the gut microbiome acts as an alternative, non-hepatic metabolic 'organ' that performs unique reductive and hydrolytic reactions, often reversing hepatic modifications. Embracing this integrated, non-sequential view is essential for a realistic understanding of drug interactions and pharmacokinetics.

Understanding the ADME framework (Absorption, Distribution, Metabolism, and Excretion) in pharmacokinetics.
Basic knowledge of chemical functional groups and reaction types, particularly oxidation, reduction, hydrolysis, and conjugation.
The concept of lipophilicity versus hydrophilicity, and how molecule polarity affects cell membrane passage and renal clearance.
Familiarity with cellular biology, specifically the role of the smooth endoplasmic reticulum and hepatocytes in the liver.
Exploring pharmacogenomics and how genetic polymorphisms in cytochrome P450 enzymes lead to 'poor' or 'ultra-rapid' drug metabolizers.
Studying drug-drug interactions (DDIs) resulting from enzymatic inhibition or induction (e.g., the effect of grapefruit juice or rifampin).
Investigating clinical toxicology, such as acetaminophen-induced hepatotoxicity through the accumulation of the toxic metabolite NAPQI.
Analyzing first-pass metabolism and its direct influence on drug bioavailability, dosing, and routes of administration.
Examining the mechanisms of renal and biliary excretion that eliminate the highly polar metabolites generated during Phase II reactions.
283.6K views4.8Klikes8:14@PillWhiteboardOriginal Release: 2017-09-23

Drug metabolism is the protective biochemical process by which the body converts hydrophobic xenobiotics into more hydrophilic metabolites for elimination; this process occurs primarily in the liver and is classified into two phases: Phase I metabolism involves functionalization reactions (oxidation, reduction, hydrolysis) that add or reveal functional groups to increase polarity, with cytochrome P450 being the primary oxidizing enzyme; Phase II metabolism involves conjugation reactions where transferases attach large polar molecules like glucuronic acid or glutathione to further enhance solubility and facilitate excretion, and the outcomes can range from producing inactive metabolites to active metabolites or even toxic metabolites depending on the specific drug and metabolic pathway involved.